Effectiveness of individualised homoeopathic medicines in managing HbA1C levels in patients suffering from Type2 Diabetes Mellitus using Synthesis Repertory.

Phase 2

Conditions: Health Condition 1: E119- Type 2 diabetes mellitus without complications

Registration Number: CTRI/2024/03/063537

Lead Sponsor: ATIONAL INSTITUTE OF HOMOEOPATHY

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

1)Patients diagnosed with Type2 Diabetes Mellitus and not taking any allopathic or other conventional treatment will be considered for the study.

2)Those who are taking hypoglycemic medication will be requested to discontinue the course for a period not exceeding 7days at whatsoever time and those agreeing to it will be considered for this study.

3)Patients whose HbA1c level is above 6.5mg/dl.

4)Adults of both gender and belonging to age group 18yrs-65yrs.

5)Subjects of all socio-economic status and all religions.

6)Patients giving written consent to participate in the study and agree to comply with protocol.

7)Illiterate patients will also be included after providing verbal explanation in vernacular language about the study and getting verbal response and written consent if they agree to participate in study.

8)Subjects who agree to undergo laboratory investigation whenever required.

Exclusion Criteria

1)Patients with insulin dependence or on any drug dependence for any chronic illness which cannot be discontinued.

2)Patients of unstable mental or psychiatric illness or suffering from any other life-threatening illness/organ failure and immune- compromised state etc.

3)Patients who are pregnant or lactating mothers.

4)Patients not willing to participate in the study.

5)Substance abuse and/or dependence.

6)Cases already undergoing homoeopathic treatment elsewhere for any chronic illness.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
HbA1c levels of each individual patient will be recorded at the time of inclusion into the study (baseline) and after 6 months of treatment, then both the data will be compared.Timepoint: HbA1c levels of each individual patient will be recorded at the time of inclusion into the study (baseline) and after 6 months of treatment, then both the data will be compared.

Secondary Outcome Measures